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No Evidence for 
Hepatitis E Virus 
Genotype 3  
Susceptibility  
in Rats
To the editor: Hepatitis E virus 
(HEV) is a positive-sense single-strand-
ed RNA virus (genus Hepevirus, fam-
ily Hepeviridae) (1). In humans, acute 
hepatitis infection caused by HEV is a 
serious public health concern in devel-
oping countries. Four HEV genotypes, 
G1–4, have been isolated from humans 
(2). G3 and G4 HEV have also been 
isolated from swine, wild boars, wild 
deer, and mongooses; these animals 
are thought to be the reservoirs of HEV 
(3). Direct evidence has indicated that 
HEV is transmitted from pigs or wild 
boars to humans; therefore, hepatitis E 
caused by G3 and G4 HEV infection is 
recognized as a zoonosis (3).
Although rats have long been 
suspected to be a potential reservoir 
for human HEV, no direct evidence 
has been found. The susceptibility 
of rats to human HEV genotypes is 
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Figure.	 Phylogenetic	 analysis	 of	 rat	 hepatitis	 E	 virus	 (HEV)	 isolated	 from	Asian	 musk	
shrews	(Suncus murinus)	in	Zhanjiang	City,	China.	Nucleic	acid	sequence	alignment	was	
performed	by	using	ClustalX	1.81	(www.clustal.org).	The	genetic	distance	was	calculated	
by	 using	 the	 Kimura	 2-parameter	method.	 The	 phylogenetic	 tree,	 with	 1,000	 bootstrap	
replicates,	was	generated	by	the	neighbor-joining	method	based	on	the	partial	sequence	
(281	nt)	of	HEV	open	reading	frame	1	of	genotype	1–4,	wild	boar,	rabbit,	ferret,	bat,	avian,	
and	rat	HEV	isolates.	The	scale	bar	indicates	nucleotide	substitutions	per	site.
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controversial. For example, anti-HEV 
IgG has been detected in various rat 
species, including Norway (Rattus 
norvegicus), black (Rattus rattus), and 
cotton (Sigmodon hispidus) rats, by 
using ELISA with antigens derived 
from G1 HEV. These results suggest 
that HEV or HEV-like virus infections 
occur in wild rats. However, the virus 
genome has not been detected, and the 
source of the infection was confirmed 
in few cases; thus far, it is not clear 
whether the anti-HEV IgG was induced 
by HEV or other HEV-like viruses. 
The detection of a partial genome of 
G1 HEV from wild rats in Nepal was 
reported in 2002 (4); however, this re-
port was retracted in 2006 because the 
isolated strain was determined to be 
a result of laboratory contamination. 
Recently, Lack et al. isolated strains of 
G3 HEV from a variety species of wild 
rats in the United States (5); this find-
ing suggests that wild rats are hosts 
for G3 HEV. Maneerat et al. also re-
ported that human HEV (presumably 
G1) was transmissible to Wistar labo-
ratory rats (6). However, Purcell et al. 
recently reported that G1, G2, and G3 
do not infect laboratory rats (7), and 
we found in a previous study that labo-
ratory rats are not susceptible to G1, 
G3, or G4 HEV (8). 
To further investigate the poten-
tial susceptibility of rats to infection 
with human HEV, we experimentally 
injected nude rats with G3 HEV and 
monitored virus growth. We used 
2 samples of G3 HEV for the infec-
tion experiments, 1 derived from fe-
cal specimens collected from a pig 
farm in Japan (GenBank accession no. 
DQ079632) and 1 derived from the 
supernatant of a hepatocarcinoma cell 
line, PLC/PRF/5, that was injected 
with the pig specimen. The infectivity 
of these samples was confirmed by ex-
perimental infections of cynomolgus 
monkeys (9; data not shown).  
Six 15-week-old female nude rats 
(athymic rats, Long-Evans-run/run; 
Japan SLC, Inc., Hamamatsu, Japan) 
were used in this study. These rats, 
which are bred to be immunodeficient, 
are known to be susceptible to rat 
HEV, but it is unknown if they are sus-
ceptible to other types of HEV. All rats 
were negative for G3 HEV RNA and 
anti-HEV antibodies, as determined 
by nested reverse transcription PCR 
(10) and ELISA (8), respectively. Rats 
were housed individually in biosafety 
level 2 facilities. Experiments were 
reviewed by the ethics committee of 
the National Institute of Infectious 
Diseases (NIID) Japan and carried out 
according to the “Guidelines for ani-
mal experiments performed at NIID” 
under code 113060. 
The 6 rats were randomly as-
signed to 2 groups, injected intrave-
nously with 500 µL of an HEV sample 
suspension through the tail vein, and 
monitored for 3 months. The 3 rats in 
group 1 were injected with the sample 
derived from pig feces, which con-
tained 5 × 104 copies of G3 HEV; the 
3 rats in group 2 were injected with 
the cell culture supernatant sample, 
which contained 4 × 106 copies of G3 
HEV. Serum samples were collected 
weekly for examination of HEV RNA 
and anti-HEV IgG and IgM and were 
also used to determine alanine ami-
notransferase values. Fecal samples 
were collected every 3 days to detect 
HEV RNA. The animals were hu-
manly killed by exsanguination 91 
days postinjection, liver tissues were 
collected, and a 10% tissue suspension 
was prepared as described (8).
For groups 1 and 2, all serum 
samples collected 1–13 weeks postin-
jection were negative for HEV RNA 
and anti-HEV IgG and IgM. HEV 
RNA also was not detected in fecal 
samples or liver tissues (Table). Ala-
nine aminotransferase elevation was 
not observed in any serum samples.
In conclusion, even by using sam-
ples with high titers of HEV RNA in 
injection experiments, we were unable 
to cause infection with G3 HEV in im-
munodeficient nude rats. We found no 
evidence that rats are susceptible to 
infection with G3 HEV.
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Fatal Case of  
Enterovirus 71  
Infection and  
Rituximab Therapy, 
France, 2012
To the Editor: Enterovirus 71 
(EV-71) causes primarily asymptom-
atic or benign infections in children <5 
years of age. However, it may cause 
severe and sometimes fatal neurolog-
ic complications, such as brainstem 
encephalitis and polio-like paralysis 
(1). Over the last 15 years, large out-
breaks of EV-71 infection have been 
described in the Asia–Pacific region, 
associated with the regular emergence 
of new genetic lineages (2). Since the 
1978 outbreak in Hungary, rare spo-
radic cases have been reported in Eu-
rope (1). In France, during 2000–2009, 
a total of 81 hospitalized patients with 
EV–17 infection were reported by the 
sentinel surveillance system, includ-
ing 2 child deaths, 1 due to proven 
rhombencephalitis (3,4). 
We report here a fatal case of EV-
71 rhombencephalitis in an immuno-
compromised adult who was receiving 
rituximab therapy. Rituximab is a chi-
meric anti-CD20 monoclonal antibody 
that is widely used for treating B-cell 
lymphoma and an increasing number of 
autoimmune diseases. Since rituximab 
became commercially available, sev-
eral infectious side-effects for the drug 
have been reported, including hepatitis 
B reactivation, progressive multifocal 
leukoencephalopathy, and enteroviral 
meningoencephalitis (5). The first 2 
cases of rituximab-associated enterovi-
ral meningoencephalitis were reported 
in 2003 (6), and 5 additional cases have 
been reported to date (7,8).
In May 2012, a 66-year-old wom-
an was hospitalized in the neurology 
unit of Bordeaux University Hospital 
with a 10-day history of fever, asthe-
nia, and psychomotor retardation. She 
had no history of travel and had not 
been in close contact with sick per-
sons. She had received a diagnosis of 
grade I follicular lymphoma 3 years 
earlier, and it had been treated with 6 
cycles of R-CHOP (rituximab, cyclo-
phosphamide, hydroxydaunorubicin, 
oncovin, prednisolone). Since July 
2010, the lymphoma had been in re-
mission, and she had been receiving 
maintenance therapy with rituximab 
since that time. The most recent ritux-
imab infusion had been administered 
in March 2012. Her condition was 
treated initially with broad-spectrum 
antibiotics and acyclovir. Still, apha-
sia, facial paralysis, spastic move-
ments, and consciousness disorders 
rapidly developed. On day 6, she was 
transferred to the intensive care unit 
for ventilatory support.
On patient’s admission, blood 
samples showed lymphopenia (0.64 × 
103 cells/mm3) and low immunoglobu-
lin levels, i.e., IgG 4.5 g/L (reference 
range 6.75–12.8 g/L) and IgM 0.33 
g/L (reference range 0.56–1.9 g/L). 
Three cerebrospinal fluid (CSF) sam-
ples were collected on days 1, 4, and 
6. CSF leukocyte count rose from 5 to 
89 cells/mm3, with lymphocytes from 
24% to 95%, and protein levels rose 
from 0.68 to 1.03 g/L (reference range 
0.15–0.45 g/L). CSF glucose level var-
ied from 3.5 to 4.5 mmol/L (reference 
range 2.7–3.9 mmol/L). Enterovirus 
RNA was detected in the patient’s 
first 3 CSF samples and in CSF, stool 
specimens, and blood until 4 weeks 
after admission (online Technical Ap-
pendix Table 1,  wwwnc.cdc.gov/EID/
article/19/8/13-0202-Techapp1.pdf). 
PCR assays of the first 3 CSF samples 
were negative for JC polyomavirus, 
herpes simplex virus, varicella-zoster 
virus, cytomegalovirus, Epstein-Barr 
virus, human herpesvirus 6, adenovi-
rus, and Toxoplasma gondii. Serologic 
tests for parvovirus B19, mumps virus, 
and measles virus were IgM negative. 
Samples were also negative for anti-
bodies against Hu, Ri, Yo, and voltage-
gated potassium channel antigens. All 
bacterial cultures were negative. No 
evidence for central nervous system 
infiltration by lymphoma cells was 
found, on the basis of CSF cytology.
Results of brain magnetic reso-
nance imaging (MRI) scans performed 
on days 2 and 6 were normal, despite 
the patient’s consciousness disorders 
(Figure, panel A). However, on day 
13, MRI scans showed bilateral and 
symmetric T2 and FLAIR hypersig-
nals in the medulla, the pons, and 
the mesencephalon, compatible with 
rhomboencephalitis (Figure, panel 
B). On day 24, the MRI scan showed 
a supratentorial extension involving 
white matter, the insular cortex, and 
basal ganglia (Figure, panel C). The 
patient’s neurologic condition dete-
riorated progressively, and she died 
of enteroviral rhomboencephalitis 32 
days after admission. 
The EV associated with the rhom-
boencephalitis was identified as an 
EV-71 genogroup C2 isolate by 1D 
gene complete sequencing and phy-
logenetic analysis (online Technical 
Appendix Figure; online Technical 
Appendix Table 2). The 1D gene se-
quences determined from cerebrospi-
nal fluid and fecal specimens from the 
patient showed 95%–97% nucleotide 
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